Microbot Medical Inc. has announced that it has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. This clearance marks the LIBERTY® System as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The approval positions the company to commercialize the LIBERTY® System in the U.S., with plans for a launch in the fourth quarter of 2025. Microbot Medical aims to transform the field by enabling access to advanced robotics without the need for traditional capital equipment and infrastructure. The company's strategy is geared toward entering a market that involves approximately 2.5 million peripheral endovascular procedures annually in the U.S.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026815), on September 08, 2025, and is solely responsible for the information contained therein.